<DOC>
	<DOCNO>NCT00415298</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , AP5346 oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This randomized clinical trial study dose AP5346 see well work compare dose oxaliplatin treat patient metastatic and/or unresectable recurrent head neck cancer .</brief_summary>
	<brief_title>AP5346 Oxaliplatin Treating Patients With Metastatic and/or Unresectable Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare delivered-dose platinum per gram wet weight single dose AP5346 v single dose oxaliplatin patient metastatic and/or unresectable recurrent squamous cell carcinoma head neck ( SCCHN ) . - Correlate platinum accumulation tumor tumor DNA clinical response patient treat regimen . - Correlate platinum accumulation tumor tumor DNA molecular tumor response determine GADD153 expression patient treat regimen . - Quantify , immunohistochemistry , expression copper transporter CTR1 , ATP7A , ATP7B SCCHN tumor correlate expression transporter tumor platinum level . - Determine response patient treat AP5346 . - Obtain additional data safety AP5346 patient . OUTLINE : This randomize , pilot study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive AP5346 IV 2 hour three time daily day 1 15 . - Arm II : Patients receive single dose unmodified oxaliplatin IV 2 hour day 1 . Beginning day 29 , patient may receive AP5346 arm I . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo tumor biopsy 24 hour first course treatment correlative pharmacological , immunohistochemical ( IHC ) , molecular study . Tumor specimen assess platinum content , GADD153 gene expression ( molecular analysis ) , copper transporter ( CTR1 , ATP7A , ATP7B ) expression IHC . PROJECTED ACCRUAL : A total 12 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary squamous cell carcinoma head neck , include oral cavity , oropharynx , hypopharynx , larynx , nasopharynx Metastatic and/or unresectable locally recurrent disease curative treatment available Patients must candidate surgical resection radiotherapy curative intent Histological documentation relapse require , especially locoregional recurrence recurrence previously irradiate field Tumor ( ) must amenable minimally invasive biopsy first course treatment Must evidence progression appearance new lesion completion radiotherapy , biopsy site previously irradiated field PATIENT CHARACTERISTICS : WHO performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Absolute neutrophil count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin &lt; 1.5 time upper level normal ( ULN ) Alkaline phosphatase ( AP ) ≤ 5 time normal ( unless elevation due bone disease bone metastasis absence liver disease ) AST ALT ≤ 3 time ULN AST ALT &gt; 3 time ULN allow provide AP ≤ 3 time ULN Blood urea &lt; 1.5 time ULN Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 60 mL/min OR creatinine clearance 24hour urine collection normal Calcium normal No history hypersensitivity reaction kind cisplatin carboplatin No serious medical condition psychiatric illness would preclude patient 's ability give inform consent receive study treatment No symptomatic peripheral neuropathy ≥ grade 2 No need IV alimentation No serious illness medical condition , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris cardiac arrhythmia Significant neurologic psychiatric disorder , include dementia uncontrolled seizure Hypophosphatemia PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior concurrent anticancer treatment ( i.e. , chemotherapy , chemoradiotherapy , radiotherapy ) At least 4 week since prior biologic therapy No prior oxaliplatin Prior cisplatin carboplatin allow No concurrent anticoagulant cardioprotective dos aspirin , cyclooxygenase 1inhibitory nonspecific antiinflammatory drug , prophylactic lowdose heparin Concurrent bisphosphonates hypercalcemia allow provide drug initiate ≥ 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>